
Amneal Pharmaceuticals, Inc.: updates and filings
Price
$21.79
November 18, 2026Market cap $7.6B
What Ploutos Investor adds for Amneal Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 3, 2026next Feb 1, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
July 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 3, 2026Results of operations, Regulation FD disclosureForm8-K
- Oct 23, 2026Financial statements and exhibits (amendment)Form8-K/A
- Sep 3, 2026Shelf registration for future offeringsFormS-3ASR
- Aug 12, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 12, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 12, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 10, 2026Material agreement entered, acquisition or disposal of assets, new material financial obligation, unregistered sale of shares, Regulation FD disclosureForm8-K
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 3, 2026Material agreement enteredForm8-K
- Jul 31, 2026Shareholder voteForm8-K
- Jul 30, 2026Additional annual meeting materialFormDEFA14A
- Jul 30, 2026Results of operations, Regulation FD disclosureForm8-K
- Jun 29, 2026Merger meeting proxy statementFormDEFM14A
- Jun 18, 2026FilingFormPREM14A
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Shareholder voteForm8-K
- May 7, 2026Results of operationsForm8-K
- Apr 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 23, 2026Additional annual meeting materialFormDEFA14A
- Apr 22, 2026Additional annual meeting materialFormDEFA14A
- Apr 22, 2026Additional annual meeting materialFormDEFA14A
- Apr 22, 2026Additional annual meeting materialFormDEFA14A
- Apr 22, 2026Additional annual meeting materialFormDEFA14A
- Apr 22, 2026Additional annual meeting materialFormDEFA14A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 3, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Oct 23, 2026 | 8-K/A | Financial statements and exhibits (amendment) | Document |
| Sep 3, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| Aug 12, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 12, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 12, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 10, 2026 | 8-K | Material agreement entered, acquisition or disposal of assets, new material financial obligation, unregistered sale of shares, Regulation FD disclosure | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 3, 2026 | 8-K | Material agreement entered | Document |
| Jul 31, 2026 | 8-K | Shareholder vote | Document |
| Jul 30, 2026 | DEFA14A | Additional annual meeting material | Document |
| Jul 30, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jun 29, 2026 | DEFM14A | Merger meeting proxy statement | Document |
| Jun 18, 2026 | PREM14A | Filing | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Shareholder vote | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| Apr 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 23, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 22, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 22, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 22, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 22, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 22, 2026 | DEFA14A | Additional annual meeting material | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Nov 21, 2017.
The full analysis
What do Amneal Pharmaceuticals's filings show?
The filings are where every one of Amneal Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.